What to do with an asymptomatic thrombus associated with cardioverter-defibrillator lead?

Jak należy postąpić z bezobjawową skrzepliną na elektrodzie defibrylującej?

Mateusz Tajstra¹, Mariusz Gasior¹, Krzysztof Filipiak², Lech Polonski¹, Marian Zembala²

¹³rd Department of Cardiology, Silesian Centre for Heart Diseases, Medical University of Silesia, Zabrze, Poland
²Department of Cardiac Surgery and Transplantology, Silesian Centre for Heart Diseases, Medical University of Silesia, Zabrze, Poland

Abstract
A 35-year-old woman received an implantable cardioverter-defibrillator (ICD) for primary prevention of sudden cardiac death. One day after implantation, transesophageal echocardiography (TEE), carried out before defibrillation threshold testing, revealed a large, mobile, grape-shaped mass attached to the defibrillator lead in the right atrium (RA), fortunately with no symptoms. Anticoagulant therapy was started immediately. Serial TEE demonstrated that, although still asymptomatic, the RA mass was enlarged. Accordingly, thrombectomy, lead extraction and placement of an epicardial ICD lead were performed. Correct pacing and defibrillation thresholds were obtained. The patient was discharged 4 days later and during 1 month follow-up remained in good condition with no recurrence of RA thrombosis.

Key words: pacing complications; lead thrombosis.

Introduction
The number of patients who receive an implantable pacemaker or cardioverter-defibrillator (ICD) is increasing continuously. Lead-induced venous thrombosis after transvenous placement of these devices is well known [1-3]. Intracardiac thrombosis is a less frequent complication, with a range of clinical manifestations and treatment options [4, 5]. This report describes a rare case of asymptomatic, right atrial (RA) thrombosis, related to the defibrillator lead, diagnosed 24 hours after implantation.

Case Report
A 35-year-old woman with chronic heart failure, New York Heart Association (NYHA) class III, due to dilated cardiomyopathy recognized 2 years earlier, was admitted to our hospital to assess suitability for orthotopic heart transplantation. An electrocardiogram (ECG) showed sinus rhythm with QRS duration of 110 ms. Transhворотarchic echocardiography (TEE) showed ejection fraction (EF) = 20%. Coronary angiography showed no coronary artery disease. There were no sinus or conduction disturbances in 24-hour ECG recording, although non-sustained ventricular tachycardia was documented. Maximal oxygen uptake volume (VO₂ max) was 14 ml/kg/min. Based on the obtained results, the patient was qualified for ICD implantation. The defibrillator lead was located in the right ventricular apex. Symptoms of transient ischemic attack (TIA) were observed during the implantation procedure; all neurological symptoms reversed after the procedure. One day later, before defibrillation threshold assessment,
transesophageal echocardiography (TEE) was performed to exclude a connection between the right and left sides of the heart. TEE showed a large, mobile, grape-shaped mass, attached to the defibrillator lead in the right atrium (RA), with no septal defects or patent foramen ovale (Fig. 1). Computed tomography (CT) also showed an RA mass, but with no vein thrombosis or pulmonary embolism (PE). The results of laboratory examinations were: leukocyte count 7500/mm; hemoglobin 12.5 g/dl; platelet count 22.5 × 10^4/mm; creatinine 0.81 mg/dl; sodium 132 mEq/l and potassium 4.1 mEq/l. D-dimer was slightly increased (0.8 μg/ml). Antinuclear antibodies, indicators of inflammation and blood culture, were negative.

Anticoagulant therapy with unfractionated heparin was started immediately, monitored using the activated partial thromboplastin time. Nevertheless, serial TEE demonstrated that the mass in RA became enlarged, although still asymptomatic (Fig. 2). A surgical intervention was decided upon. On cardiopulmonary bypass, atriotomy revealed a clot adherent to the lead (Fig. 3). The ICD lead was cut and extracted with the adherent thrombus (Fig. 4). The ICD box and the remaining part of the lead were removed. The atrium was sown and an epicardial pacing and defibrillator leads were placed. Correct pacing and defibrillation thresholds were obtained. Cultures made from the material obtained during the surgical removal were negative. The patient was discharged 4 days later and during 6-month follow-up remained in good condition without recurrence of RA thrombosis.

Discussion

In this report, we present a case of rare RA thrombosis in a young woman. The condition was diagnosed one day after ICD implantation.

Venous thrombosis associated with pacemaker leads is a well-known phenomenon that can occur in almost 20-40% of patients. Fortunately, with the development of venous collateral circulation, symptomatic vein thrombosis occurs in only 1-3% of the cases [6, 7]. Floating intracardiac thrombi attached to the pacing lead are uncommon, but potentially very dangerous due to the high risk of PE.

Several possible mechanisms of pacemaker lead thrombosis have been postulated: the long-term presence of
permanent pacemaker leads; inflammation and fibrosis alongside the lead; multiple pacemaker leads increase the total surface area for thrombus formation; another intervention (e.g. upgrade procedure), particularly within a short time frame; and thicker defibrillator leads may cause intracardiac endothelial injuries with subsequent thrombus formation. Congestive heart failure, prothrombotic states (connective tissue disease, cancer, thrombophilia, and others) or pacemaker lead injury may predispose to lead-associated thrombosis. In our patient, congestive heart failure was the most likely predisposing factor, although the time to lead thrombosis was very short. The manufacturer’s expert report failed to demonstrate any damage of the implanted thrombus-related lead.

Intracardiac lead-associated thrombosis may have a variety of clinical manifestations, ranging from asymptomatic course to heart failure, shock, respiratory failure and cyanosis, edema and infectious symptoms. There are several imaging techniques used in diagnosing intracardiac pacing lead thrombosis. TEE facilitates the exploration of cardiac structures and the great vessels without false anatomical images, which is why some authors suggest that it should be the initial imaging technique of choice in these patients. TTE, on the other hand, is a simple and widely available tool used to evaluate signs of right ventricular overload; however, it provides poor sensitivity, especially in the presence of small thrombi, which can be easily overlooked [8]. In some cases, cardio-CT or percutaneous venography may be used; however, these techniques are not as available as echocardiography. Cardio-magnetic resonance is contraindicated in patients with IP and ICD.

The treatment strategy for intracardiac thrombosis associated with IP or ICD leads has been widely discussed and still remains controversial. Treatment modalities include medical management with antiplatelet and/or anticoagulation and/or thrombolysis, percutaneous intervention, surgical extraction or combined medical and interventional procedures. In our opinion, the choice of treatment should be determined by patient age, comorbidities, size, location and duration of the thrombosis and especially by the type of symptoms. Although in our patient the complication was clinically silent, surgical treatment was decided upon since a mobile thrombus carries a high risk of PE and paradoxical embolism. Additionally, despite immediate anticoagulant treatment, the thrombus became larger. Thus, in our opinion, the treatment strategy should be individualized until more clinical data are available.

References